Synopsys saw its IBD SmartSelect Composite Rating jump to 98 Wednesday out of a best possible 99, up from 94 the day before. The chip design software maker's sales and profits have risen over the past year and Synopsys stock hit an all-time high a month ago. The revised score means the stock currently tops 98% of all other stocks in terms of key performance metrics and technical strength.